BUSINESS● LOW6h ago · Oct 14, 2026, 4:53 PM
IDEAYA resumed at Buy at Stifel on combo treatment for uveal melanoma
Seeking Alpha Tech · global
IDEAYA stock has resumed with a 'Buy' rating from Stifel, specifically noting its combination treatment for uveal melanoma. This indicates a positive market outlook for the company, tied to its medical advancements.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS24m agoHow Jardine Matheson’s street-shop sale reflects Hong Kong retail property’s strugglesSouth China Morning PostBUSINESS44m agoMetrotel takes over part of Telefónica's customers and becomes Argentina's third operatorClarín